Velpatasvir and Sofosbuvir
Epclusa, Sofosbuvir and Velpatasvir
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
NADAC/unit
$278.1592
No Shortage
Tier 1: 41.3%
PA Req: 217.9%
vs. brand Epclusa: Generic saves up to -2682% per unit
Market Intelligence
2025-04-16 Class II Recall: ASEGUA THERAPEUTICS LLC
Generic Manufacturers
GILEAD SCIENCES INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.